Partner Article
Aesica to concentrate investment in lucrative German formulations business
Aesica Pharmaceuticals, which operates North East bases in Newcastle and Cramlington, says it is investing in its German operations in Zwickau.
The developer and manufactuer of pharmaceuticals is adding new roller compaction technology to the plant after identifying it as a key growth market within Germany.
Aesica has also recently invested in a tablet coating and pouch packing line facilties in the region.
Ian Muir, managing director, Finished Dose at Aesica commented: “This new investment aligns with our strategy of investing in our German sites to broaden capabilities, which is expanding our domestic market share within Germany, whilst allowing us to offer new services to our global customers.
“The dry granulation capability will drive business growth as customers with moisture sensitive APIs seek appropriate technologies, and crucially, experienced CDMOs that can deliver their products.”
This was posted in Bdaily's Members' News section by Tom Keighley .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.
Construction must be built on commercial discipline
Devolution needs financial firepower to drive growth
The value of creating a stronger careers route
Apprenticeships: Invest in talent or keep chasing it
Are you ready for salary transparency?
Confidence the key to our artificial intelligence future
The missing piece of the puzzle in the NEET crisis
The North East investment story needs two engines
We must forge change to close the skills gap
Creating the conditions for North East talent to thrive
Time to end London monopoly on arts talent
Why local government is key to devolution success